Tech Company Financing Transactions
Character Biosciences Funding Round
On 9/17/2025, Character Biosciences received Series B funding from Sanofi Ventures and private investors.
Transaction Overview
Company Name
Announced On
9/17/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Sanofi Ventures (Jason Hafler)
Proceeds Purpose
Proceeds from the financing will enable Character Bio to further advance the clinical development of CTX114, a complement inhibitor for geographic atrophy (GA), and CTX203, a lipid modulator designed to prevent progression to advanced age-related macular degeneration (AMD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
155 Second St
Jersey City, NJ 07302
USA
Jersey City, NJ 07302
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Character's approach integrates genomics, longitudinal clinical and imaging data, machine learning to identify the genetic drivers of disease progression and develop innovative therapies. Since inception, we have built Character Bio to be a patient-driven therapeutics company. We partner with patients, providers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cheng Zhang
Browse more venture capital transactions:
Prev: 9/17/2025: Druid venture capital transaction
Next: 9/17/2025: Mongoose Software venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs